HEALTH-2007-2.4.1-2
HEALTH-2007-2.4.1-2
6 projects · €17,182,184 total EU contribution (project-level) · 44 participating organizations · 17 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€17,182,184
Countries active
Participant organizations by country (headquarters in CORDIS).
- Germany (8)
- UK (6)
- France (5)
- Spain (4)
- CH (3)
- DK (3)
- Netherlands (2)
- RO (2)
- SE (2)
- EL (1)
- FI (1)
- IS (1)
- LU (1)
- PL (1)
- PT (1)
- SK (1)
- US (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III3 projects · ES
- THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE2 projects · UK
- UNIVERSITY COLLEGE LONDON2 projects · —
- AUH1 projects · DK
- AUH/S1 projects · DK
- ANTIGONE1 projects · UK
- ASSISTANCE PUBLIQUE HOPITAUX DE PARIS1 projects · FR
- BRUNEL UNIVERSITY LONDON1 projects · UK
- CHARITE - UNIVERSITAETSMEDIZIN BERLIN1 projects · DE
- CEA1 projects · FR
- DS1 projects · CH
- LSOC1 projects · PL
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Identification and validation of new breast cancer biomarkers based on integrated metabolomics METACANCER · 200327 | FP7 | €2,873,205 | €3,687,434 | Details |
Novel MS-based strategies to Discover and Evaluate Cancer Biomarkers in urine: Application to Diagnosis of Bladder Cancer DECANBIO · 201333 | FP7 | €2,907,412 | €3,910,867 | Details |
Discovery of novel cancer serum biomarkers based on aberrant post translational modifications of O-glycoproteins (O-PTM-Biomarkers) and their application to early detection of cancer O-PTM-BIOMARKERS · 201381 | FP7 | €2,848,153 | €3,847,340 | Details |
Genetic prostate cancer variants as biomarkers of disease progression PROMARK · 202059 | FP7 | €2,709,577 | €4,045,219 | Details |
Identification and characterization of novel human telomere-related biomarkers that aid cancer management by improving patient diagnosis, treatment selection, response monitoring, and drug development TELOMARKER · 200950 | FP7 | €2,848,490 | €3,683,902 | Details |
Prediction of bladder cancer disease course using risk scores that combine molecular and clinical risk factors UROMOL · 201663 | FP7 | €2,995,347 | €3,922,796 | Details |